专利号:US-9353057-B2 优先权日:2003-12-30 标 题:Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof 发明人:GALLOP MARK A; DAI XUEDONG; SCHEUERMAN RANDALL A; RAILLARD STEPHEN P; MANTHATI SURESH K; YAO FENMEI; PHAN THU; LUDWIKOW MARIA; PENG GE; BHAT SEEMA 权利人:XENOPORT INC 摘要:Methods for synthesis of 1-(acyloxy)-alkyl carbamates, particularly, the synthesis of 1-(acyloxy)-alkyl carbamate prodrugs of primary or secondary amine-containing drugs are described. Also described are methods for synthesis of 1-(acyloxy)-alkyl N-hydroxysuccinimidyl carbonates which are useful intermediates in the synthesis of 1-(acyloxy)-alkyl carbamates are also described.
专利号:US-2015158809-A9 优先权日:2013-02-26 标 题 :Method of making 1-(acyloxy)-alkyl carbamate compounds 发明人:WANG HUAN; LIU PENG; DAI QUNYING; YIN HAO; RAILLARD STEPHEN P 权利人:XENOPORT INC 摘要:Methods of preparing carbamate prodrugs of amine-containing drugs are provided. Carbonates useful in the synthesis of the carbamate prodrugs are also provided.
专利号:EP-1713801-B1 优先权日:2004-02-02 标 题:Process for preparation of 1-(2s,3s)-2-benzhydr yl-n-(5-tert-butyl-2-methoxybenzyl)quinuclidin-3-amine 发明人:BASFORD PATRICIA ANN; POST RONALD JAMES; SMITH JULIAN DUNCAN; TABER GERALDINE PATRICIA 权利人:PFIZER PROD INC 摘要:This invention relates to an improved process for the preparation of (2S,3S)-Â 2-benzhydryl-N-(5-tent-butyl-2-methoxybenzyl)quinuclidin-3-amine, (hereinafter 'compound of Formula I') and its pharmaceutically acceptable salts. In particular, the invention is directed to an improved synthesis of the monohydrate citrate salt of the compound of Formula (la).
专利号:WO-2009094569-A2 优先权日:2008-01-25 标 题:Method for the enzymatic kinetic resolution of acyloxyalkyl thiocarbonates used for the synthesis of acyloxyalkyl carbamates
专利号:US-2005222431-A1 优先权日:2003-12-30 标 题:Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
专利号:US-7227028-B2 优先权日:2003-12-30 标题 :Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
1: Myers J, Voges A, Werner R, Ritter N. Maropitant Citrate Administration Significantly Decreases the Rate of Peristalsis in the Stomach and Jejunum and Does Not Significantly Alter Intestinal Diameter or Intestinal Wall Thickness in Healthy Adult Dogs. Vet Radiol Ultrasound. 2026 May;67(3):e70167. doi: 10.1111/vru.70167. 90(2):59-64. 3: Gould AG, Akucewich LH, Thomas RC, Lewis ST, Ghubash R. Influence of Maropitant Citrate on Pollen and Control Intradermal Test Reactivity in Atopic Dogs: A Randomised, Controlled, Blinded Trial. Vet Dermatol. 2025 Dec 25. doi: 10.1111/vde.70045. Epub ahead of print. 50(1):17. doi: 10.1007/s11259-025-10966-8. 35(3):197-206. doi: 10.1111/vec.13476. Epub 2025 Jun 16. 86(7):ajvr.25.02.0040. doi: 10.2460/ajvr.25.02.0040. 27(2):1098612X241309826. doi: 10.1177/1098612X241309826. 9: Gölgeli Bedir A, Yanmaz LE, Okur S, Şenocak MG, Turgut F, Kocaman Y, Orhun ÖT, Ersöz U, Baykal B. The Effect of Maropitant, Ondansetron and Metoclopramide on Dexmedetomidine-Induced Vomiting in Cats. Vet Med Sci. 2025 Jan;11(1):e70152. doi: 10.1002/vms3.70152.
合成参考文献
参考文献:10.2460/javma.21.02.0082 摘要:Burke JE, Hess RS, Silverstein DC. Effectiveness of orally administered maropitant and ondansetron in preventing preoperative emesis and nausea in healthy dogs premedicated with a combination of hydromorphone, acepromazine, and glycopyrrolate. J Am Vet Med Assoc. 2021 Dec 15;260(S1):S40–5. doi: 10.2460/javma.21.02.0082.